CN Patent

CN121712526A — 抗cd5抗体及其用途

Assigned to Hinthers Therapeutics Inc · Expires 2026-03-20 · 0y expired

What this patent protects

本公开涉及抗CD5抗体及其用途，包括ALK5‑抗体缀合物及其用于治疗癌症的用途。

USPTO Abstract

本公开涉及抗CD5抗体及其用途，包括ALK5‑抗体缀合物及其用于治疗癌症的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN121712526A
Jurisdiction
CN
Classification
—
Expires
2026-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Hinthers Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.